Previous 10 | Next 10 |
It is a great time to be investing in healthcare stocks. Sentiment is not overly positive and Medicare For All remains an overhang (it will not be implemented within the next ten years), yet I maintain that the outlook for continued growth, driven by the prevalence of chronic disease and demog...
Axovant Gene Therapies (NASDAQ: AXGT ) is up 29.4% after an initiation at Outperform by SVB Leerink on a number of factors, chiefly the company's Parkinson's disease program. More news on: Axovant Gene Therapies Ltd., Healthcare stocks news, Stocks on the move Read more ...
ContraVir Pharmaceuticals (NASDAQ: CTRV ) +42% on FDA reaction to CRV431 plans. More news on: ContraVir Pharmaceuticals, Inc., Axovant Gene Therapies Ltd., Seadrill Limited, Stocks on the move, Read more ...
Guardion Health Sciences (NASDAQ: GHSI ) +35% on receiving a patent from the European Union for its proprietary medical device, the MapcatSF. More news on: Guardion Health Sciences, Inc., DiaMedica Therapeutics Inc., Melinta Therapeutics, Inc., Stocks on the move, Read more .....
Axovant Gene Therapies (NASDAQ: AXGT ) and Yposkesi form a strategic partnership for preferred access and reserved capacity for cGMP grade viral vector production. More news on: Axovant Gene Therapies Ltd., Healthcare stocks news, Stocks on the move, Read more ...
BASEL, Switzerland and CORBEIL-ESSONNES, France, June 20, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announces it has signed a strategic partnership with Yposkesi, a leading Contract Development a...
Synlogic (NASDAQ: SYBX ) +26% as Ginkgo Bioworks to invest $80M . More news on: Synlogic, Inc., Bridgeline Digital, Inc., MagnaChip Semiconductor Corporation, , Stocks on the move Read more ...
Gainers: MX +16.9% . AXGT +15.5% . MAT +8.7% . NBY +6.7% . NVTR +5.5% . More news on: MagnaChip Semiconductor Corporation, Axovant Gene Therapies Ltd., Mattel, Inc., Stocks on the move, , News on ETFs Read more ...
Axovant Gene Therapies (NASDAQ: AXGT ): Q4 GAAP EPS of -$0.45. More news on: Axovant Gene Therapies Ltd., Earnings news and commentary, , Read more ...
Established diversified pipeline of three clinical-stage gene therapy programs for serious neurological disorders including Parkinson’s disease, GM1 gangliosidosis, and Tay-Sachs SUNRISE-PD Phase 2 trial of AXO-Lenti-PD for Parkinson's disease continues to enroll patients i...
News, Short Squeeze, Breakout and More Instantly...
Axovant Gene Therapies Ltd. Company Name:
AXGT Stock Symbol:
NYSE Market:
On-track to report t opline r esults from low-dose cohort by end of 2020 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to ra...
A pioneering researcher , Dr. Gao has made foundational contributions to the discovery of novel AAV vectors for gene therapy Dr. Gao recently served as President of the American Society for Gene and Cell Therapy (ASGCT) and has been ranked as one of...
Rebranding to Sio Gene Therapies to reflect an independent company with a scientific strategy focused on disease-modifying and curative genetic medicines Company’s common stock will trade on the NASDAQ under new ticker “SIOX” effective November 13, 2020 ...